RESULTS: By Day 7 of storage, units illuminated on Day 4 showed a smaller impact of the PI process than units treated on the day of production or one day after on PLT quality such as PLT activation; metabolic activity; microvesicle and EGF release; and phosphorylation of p38, ERK, and HSP27. PCs treated on Day 3 of storage displayed an intermediate effect.
CONCLUSION:
The timing of PI treatment of PCs influences in vitro PLT quality. Based on these results, timing recommendations should be reconsidered. If PI is applied, inventory management in blood banks might improve with a more flexible collection and treatment regime. P latelet (PLT) transfusions continue to be vital for treating patients with qualitative and quantitative PLT disorders. These treatments are associated with both immune and nonimmune reactions due at least in part to contaminating white blood cells (WBCs). 1 Despite improved donor screening and implementation of safety procedures, bacterial contamination of PLT concentrates (PCs) still represents a major infectious risk. 2, 3 Most transfusion-transmissible infectious agents as well as donor WBCs can be inactivated by pathogen inactivation (PI) technologies. 4 The three systems currently on the market 5 a photosensitizer to target the nucleic acid of pathogens to prevent their proliferation. 6 They have been shown to be efficacious in the inactivation of a variety of bacteria and certain viruses and parasites 7 and most recently a study demonstrated that the riboflavin and UV light technology has the ability to prevent transfusion transmission of malaria. 8 Consequently, their application to PCs has been linked to discussions about the possible extension of the shelf life of PCs as treatment reduces the risk of clinically significant bacterial contamination associated with longer storage time. 9, 10 However, the challenge for all PI technologies is to maintain adequate clinical efficacy through retention of the biologic functions of the treated blood product while achieving adequate pathogen reduction levels. 10, 11 Several research studies have demonstrated a negative impact on in vitro PLT quality. 7 The application of these different PI technologies to PCs revealed that some in vitro variables deteriorate after treatment and subsequent blood bank storage including increased glucose metabolism, consequent lactate production, and pH decrease; increased Pselectin expression; reduced responsiveness to agonists; and decreased mitochondrial activity possibly linked to increased apoptosis. 12, 13 Observed increases in glucose consumption as well as mitochondrial activity may stem from an increased demand for ATP due to an increased release of a-granules. 14 Due to differences in the chemistry of the individual PI technologies, their effects on in vitro quality vary as reflected in the different protein and signaling profiles seen in proteomic comparisons. 15 Furthermore, studies of the recovery and survival of pathogen-reduced PCs in healthy individuals demonstrate a reduction in recovery compared to the control and survival is similarly shortened. 10, 16, 17 These findings demonstrate a negative impact of PI on PLT efficacy; however, there appears to be little clinical impact for the treatment of hypoproliferative thrombocytopenia beyond possible shortening of the transfusion interval, which could result in an increased usage of pathogen-reduced PCs. [18] [19] [20] To develop strategies to minimize the negative effects of PI, the modulation of the PI processes and/or component production might help to fine-tune these technologies. The reduction in PLT in vitro quality upon PI treatment could be at least in part explained by the double stress PLTs undergo during production and subsequent PI by UV illumination of PCs. Therefore, it was hypothesized that a delay in the illumination step separated from the physical stress to the PLTs during the production procedure might provide the PLTs with more time to recover to better withstand the PI treatment and shorten the storage time after treatment. This assumption is based on the observation that some of the features caused by stress are partly reversible. Here we analyzed the impact of PI treatment timing on PLT in vitro quality throughout storage using the Mirasol PI system, which utilizes riboflavin and UV light. This study demonstrates that delaying the PI treatment by more than 72 hours significantly reduced the negative impact on the PLT in vitro quality assessed on Day 7 of storage compared to illumination within 24 to 48 hours after production.
MATERIALS AND METHODS

Materials
Common chemicals were purchased from Sigma-Aldrich or Fisher Scientific.
Blood plateletpheresis
This study was approved by the Research Ethics Board of Canadian Blood Services and informed consent was obtained from all healthy volunteers before donation. Phlebotomy and plateletpheresis were carried out by the development laboratory of Canadian Blood Services (net-CAD). Leukoreduced, double PCs collected by apheresis on an apheresis machine (Trima Accel, TerumoBCT) were divided into two equal units after a 2-hour resting period.
Study design and sample preparation
Double apheresis PCs collected in plasma were treated in combination on Day 0 (day of donation, T0), Day 1 (T1), Day 3 (T3), or Day 4 (T4) of storage using the Mirasol system (TerumoBCT) or kept untreated as control (C). This setup produced a total of n 5 10 for each condition (C, T0, T1, T3, and T4). The PI treatment was carried out according to the manufacturer's protocol with 35 mL of riboflavin (500 lmol/L) added before illumination or 35 mL of saline added to the untreated control as volume compensation. Samples were collected on Days 1, 5, and 7 of storage; the PLT lysates and supernatant (releasate) were prepared in a two-step process: PCs were pelleted at 200 3 g for 5 minutes and frozen until use. The supernatant was centrifuged again at 2060 3 g for 10 minutes to obtain the releasate for protein analyses and microvesicle enumeration. For the PLT lysis, the pellet was dissolved in a buffer containing 1% Triton X-100, 2 mmol/L EDTA in phosphate-buffered saline (PBS) supplemented with protease and phosphatase inhibitors (Roche).
Analyses of PCs
Methods to assess the in vitro PLT quality are summarized in Table 1 . PLT count and mean PLT volume were measured on a hematology analyzer (ADVIA 120, Siemens). Metabolites (glucose, lactate, and pH measured at 378C and corrected to 258C) were quantified using a blood gas analyzer (Gem Premier 3000, Instrumentation Laboratories). If lactate levels were out of the range of the analyzer, the samples were diluted with PBS and retested. PLT activation was monitored by the expression of P-selectin (CD62P) on the PLT surface using flow cytometry. Briefly, Signs of apoptosis were monitored by changes in the exposure of phosphatidylserine on the PLT surface using annexin V binding. The PLT sample was diluted with PBS to a count of 100 3 10 9 PLTs/L; incubated for 30 minutes with annexin V-fluorescein isothiocyanate (BD Biosciences) in a binding buffer containing 10 mmol/L Hepes adjusted to pH 7.4, 140 mmol/L NaCl, and 2.5 mmol/L CaCl 2 ; and analyzed by flow cytometry. All PLT units were tested for sterility after sampling on Day 7 by plating an aliquot on a blood agar plate (VWR) followed by incubation for 24 hours at 378C. No samples showed any growth.
Immunoblot analyses
For protein analyses, washing and lysis procedures were performed as described previously. All samples were handled in a consistent manner to minimize any manipulation artifacts. PLT lysates were separated on sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels and blotted onto nitrocellulose membranes (Bio-Rad). Membranes were probed with primary antibodies against p38 (Santa Cruz Biotechnology); ERK, HSP27, phospho-HSP27, thrombospondin (TSP), and platelet factor 4 (PF4; Cell Signaling); phospho-p38 and phospho-ERK (Signalway); and actin (Sigma-Aldrich) followed by labeling with their respective secondary antibodies (LI-COR Biosciences). Protein band intensities were quantified by densitometry using the imaging analysis software Odyssey on the LI-COR bioimaging system.
Enzyme-linked immunosorbent assay
Previous studies have shown that a-granule proteins are released upon riboflavin and UV light treatment; 21 therefore, PF4 and TSP were analyzed by immunoblot and levels of the epidermal growth factor (EGF) in the supernatant were determined by enzyme-linked immunosorbent assay (ELISA; RayBiotech) according to manufacturer's instructions as EGF levels were too low for immunoblot analyses. A 1:5 dilution of the PLT supernatant in PBS buffer was used and the ELISA plates were analyzed on a plate reader (Spectra Max 190, Molecular Devices).
Microvesicle enumeration
Platelet-poor plasma was collected by centrifugation of PCs twice at 1000 3 g at room temperature and then diluted 10-fold with PBS buffer containing 0.25% bovine serum albumin and 200 mmol/L NaCl. Ten microliters of the diluted PLT-poor plasma was incubated with 5 lL of CD41-PC5 (Beckman Coulter, Inc.) to label glycoprotein IIb in a total volume of 50 lL. After incubation for 40 minutes at room temperature in the dark, 10,000 polystyrene counting beads (Polysciences, Inc.) and PBS buffer were added to a final volume of 1 mL before analyzing by flow cytometer (FACSCanto II, BD Biosciences). Onethousand counting beads were collected for each sample and the respective counts of PLT microvesicles were determined.
Statistical analysis
Statistical analyses were performed applying mixed model analyses with computer software (SAS, Version 9.3, SAS Institute, Inc., 2020-2010) followed by a post-hoc test with Tukey adjustment to determine statistical differences between treatments and storage days. Significance was accepted at a p value of less than 0.05.
RESULTS
Impact of PI timing on in vitro PLT quality
Alterations in PLT metabolism were monitored by pH and levels of glucose and lactate. The pH was maintained on Days 1 and 5 in all units. On Day 7 of storage, PI treatment on Days 0 and 1 (T0 and T1, respectively) had the strongest effect showing a reduction compared to the untreated control (Fig. 1A) . In contrast, PI treatment on Days 3 and 4 (T3 and T4, respectively) displayed a moderately increased pH value on Day 7 of storage similar to the untreated control. Glucose levels were lower in the T0 units compared to the control units; however, delay of the treatments resulted in stepwise higher glucose levels both on Days 5 and 7 of storage with levels in T4 units significantly higher compared to T0 units (Fig. 1B) . glucose level trend was mirrored in the lactate levels showing the typical increase in lactate production upon PI treatment and similarly a stepwise reduction with the PI treatment delay (Fig. 1C) . Levels of lactate in the T4 units on Days 5 and 7 of storage were significantly reduced compared to T0 units and were similar to the untreated controls of the individual storage days. The corresponding lactate production rate was 0.05 6 0.02 and 0.12 6 0.02 mmol/L/hr as well as 0.07 6 0.01 and 0.15 6 0.03 mmol/ L/hr before and after the T0 or T4 illumination, respectively. The untreated control units exhibited a 0.07 6 0.01 mmol/L/hr lactate production rate.
PLT activation was determined by the expression of Pselectin on the PLT surface. Degranulation levels increased upon PI treatment on both Day 5 and Day 7 of storage as observed in previous studies (Fig. 1D) . Delaying treatment by 1 day had no impact on the PLT activation level; however, T3 and T4 units showed a significant reduction in activation compared to T0 or T1, almost to the level of the untreated units.
The in vitro responsiveness of PLTs to agonists is generally predictive of their overall functionality. Two different analyses were applied, response to the agonist ADP on degranulation as described and the ESC as it reflects the degree of agonist-induced actin rearrangement. The response to degranulation was reduced due to the PI treatment as observed previously (Fig. 1E) . On Days 5 and 7, compared to T0 units, responsiveness was significantly improved in T3 and T4 units and was at a similar response level as the untreated control unit. Similarly, response to ADP determined by ESC was strongly reduced upon illumination and improved stepwise with the treatment delay (Fig. 1F) . Signs of apoptosis development were monitored by binding of annexin V to surface-exposed phosphatidylserine. PI treatment caused an increase in apoptosis development with storage time (Fig. 1G) . Delaying illumination reduced the flipping of the membrane phosphatidylserine moieties in a stepwise manner, as seen with other variables. On Days 5 and 7 units treated on Day 3 (T3) and Day 4 (T4) showed significantly reduced annexin V binding, respectively, compared to the T0 units.
Impact of PI timing on protein kinase activation
In a previous study we found that riboflavin and UV light treatment caused an increase in phosphorylation of a variety of protein kinases. 22 In this study, levels of phosphorylated p38 MAPK, HSP27, and ERK were analyzed by immunoblot. Storage-dependent increases in phosphorylation levels were detectable for all three proteins analyzed which were further increased upon T0 and T1 PI treatment on Day 7 of storage ( Figs. 2A and 2C ). Delayed treatment to Day 3 (T3) and Day 4 (T4) resulted in a reduced level of kinase and kinase substrate activation, which was significantly different on Day 7 compared to early treatments (T0 and T1) and which was not seen for ERK phosphorylation (Fig. 2E ). In the same samples, the total expression of all proteins tested was not affected both throughout storage and upon illumination (Figs. 2B, 2D , and 2F).
Impact of PI timing on the releasate of selected proteins
Levels of a-granule proteins such as PF4, TSP, and EGF were monitored in PLT releasates. All proteins monitored were released from the granules as part of the storage lesion process (Figs. 3A-3C ). PI treatment accelerates the degranulation seen in the T0 and T1 treated samples. T3 and T4 treated samples displayed significantly reduced protein levels of TSP and PF4 almost showing similar levels as the untreated control.
Impact of PI timing on the PLT microvesicle release
Release of microvesicles from PLTs was monitored in the samples as count per microliter of PC in the presence of control beads. A storage-dependent increase was observed while T0 illumination caused an immediate increase on Day 1, which continued throughout storage (Fig. 4) . T3 and T4 treatments showed a stepwise reduction in microvesicle release on both Day 5 and Day 7 of storage with T4 significantly different compared to T0 treated samples. 
DISCUSSION
PI technologies for blood and blood products inactivate a broad spectrum of pathogens and were developed to improve safety. 7 However, several research and clinical studies have shown different degrees of impact on product in vitro quality and transfusion outcome caused by the treatment, respectively. 10 Proteomic studies have tried to understand molecular mechanisms triggered in PLTs by these PI systems. 15 With these data and successive protein analyses, signaling pathways have been identified that seem to become activated upon PI treatment. Targeted inhibition of protein activities involved in these pathways showed improved PLT in vitro quality after riboflavin and UV light treatment and storage leading to molecular models forming a platform to fine-tune these technologies. 12, 22 In this study another variable in the system was modulated: treatment timing. Following the manufacturer's guidelines, early treatment (within 22 hr) was designed to inactivate any potential pathogens, ideally at initial low concentrations. However, from a PLT point of view, the insult triggered by the illumination might be adding to negative effects of production leading to a cumulative impact on the in vitro quality of the PCs. Based on this hypothesis, separating these two events by time might result in decreased damage to the PLT throughout storage by providing some resting time to recover from the production process. It is known that certain damage to PLTs such as production-induced stress responses is reversible. 23, 24 The concept to separate these two processing steps shortens the storage time after treatment and is further supported by previous proteomic analyses of PCs during storage demonstrating that the PLT protein profile is less dynamic 1 day after compared to the day of production.
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PLT in vitro quality with a delayed PI treatment schedule was analyzed and compared to the timing currently recommended by the manufacturer. In vitro data obtained clearly demonstrate that the delay of treatment by 3 (T3) or 4 (T4) days has a less negative impact on the in vitro quality on Day 7 of storage compared to illumination on the day of production (T0) or 1 day later (T1).
Metabolism is less accelerated in units treated later in the storage process compared to early treatment, with in vitro data for pH values and glucose and lactate levels of the T4 units almost identical to the untreated units. Similarly, PLT activation and the functional assay examining the response to the agonist ADP demonstrated less degranulation in T4 units compared to the untreated units on both Day 5 and Day 7 of storage. This reduced activation level is reflected in an improved response capacity in this study tested as the degranulation ability which was again similar to the untreated units. This result was in line with the observation that the release of both a-granule proteins and PLT microvesicles was significantly reduced when PI was delayed compared to early treatment. Finally, in a previous study we had profiled the activation level of a series of proteins kinases upon riboflavin and UV light treatment resulting in enhanced phosphorylation after illumination, but different intensities. 22 Furthermore, the phosphorylation levels for p38 MAPK and HSP27, but not ERK, correlated strongly with PLT activation determined by the surface expression of P-selectin. This marker proved to be valuable as its expression was decreased in units that were PI treated later. This observation further supports the model that the p38 MAPK-HSP27 signaling cascade is activated upon riboflavin and UV light treatment and is involved in regulating certain PLT functions such as degranulation or microvesicle release. The data collected in this study were analyzed to compare the in vitro quality of units treated later versus early after production and subsequent storage. Alternatively, the in vitro quality data could be evaluated dependent on the pretreatment time and a subsequent equal storage time posttreatment. PCs that were PI treated on Day 1 had Day 5 characteristics almost identical to the Day 7 results of PCs that had been PI treated at Day 3 suggesting that the PLT quality seems to be affected by the pretreatment time.
Despite the broad and effective inactivation capacity of the diverse PI technologies, consideration must be given to the potential impact of delayed treatment on PI effectiveness. Although a previous study comparing the effectiveness of the riboflavin and UV light treatment with bacterial culture testing demonstrated that up to 98% protection against 13 tested bacterial strains could be achieved, 26 with delayed PI treatment, it may be necessary to retain routine bacterial testing such that only culture negative units are considered for delayed PI treatment. This concern arises as certain bacteria can grow to high bacterial titers by Day 3 or Day 4 of storage. 27 A previous study has demonstrated that photochemical treatment did not inactivate one of 15 bacterial strains tested in apheresis PLTs stored in PAS with a 30-hour delay between contamination and treatment, but was able to inactivate all tested bacteria strains with a 24-hour delay. 28 Although the riboflavin and UV light PI treatment has been shown to efficiently inactivate high titers of a variety of bacterial strains in PCs, 29 the bacterial inactivation efficacy in this delayed PI-timing setting needs to be assessed. In addition, bacterial endotoxins could accumulate during the growth phase until PI treatment causing an adverse transfusion event in the transfusion recipient.
In conclusion, the results from this study show that further efforts are necessary to find the best balance between PI and the preservation of product in vitro quality. This concept suggests that inventory management in blood banks might improve due to a more flexible collection and treatment regime, especially in the light of a potential extension of the shelf life of PCs. 
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